AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05585294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.
Study NCT05053685 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Urine and plasma metanephrines
Description: Measurement of Urine and plasma metanephrines
Study NCT02729415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stromal Vascular Fraction Cells (SVF Cells) Injection
Description: The procedure involves the injection of stromal vascular fraction cells (SVF Cells) into the scalp. The injection will be performed once in the middle of two perpendicular sides of a 2 x 2 cm area.
Study NCT02729415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Tissue collection involving the micro-harvest of subcutaneous adipose tissue to harvest the stromal vascular fraction cells (SVF Cells).
Study NCT02729415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair Measurements
Description: Hair measurements will be performed using a computerized handheld USB camera at baseline, 6 weeks, and months 3 and 6 after treatment.
Study NCT00375713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: 1 Levocetirizine 5mg tablet per day before bedtime for 14 days
Study NCT00375713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: 1 Cetirizine 10mg tablet per day before bedtime for 14 days.
Study NCT00375713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Levocetirizine
Description: 1 Placebo-Levocetirizine tablet per day before bedtime for 14 days
Study NCT00375713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-Cetirizine
Description: 1 Placebo-Cetirizine tablet per day before bedtime for 14 days
Study NCT00375713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard topical steroid (1% hydrocortisone) ointment
Description: 1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
Study NCT00375713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard topical steroid (1% hydrocortisone) ointment
Description: 1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
Study NCT02749916 — intervention group
Intervention type: OTHER
Intervention: Methods of carotid wall imaging
Study NCT01139515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan commercial tablet
Description: 20 mg tablet, single dose
Study NCT01139515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan commercial tablet
Description: 40 mg tablet, single dose of 1 X 40 mg
Study NCT01139515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan commercial tablet
Description: 40 mg tablet, single dose of 2 X 40 mg
Study NCT01139515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan commercial tablet
Description: 40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
Study NCT00095576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10\^10 adenovirus genomes \[ad-vg\]/dose).~This dose is equivalent to 3x10\^10 vp/dose used in study V520-016.
Study NCT00095576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
Study NCT04448379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: IV infusion Q2W for 4 weeks (28-day cycles)
Study NCT01512576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter
Study NCT01512576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation
Description: 1 treatment session of 30 minutes
Study NCT03999476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ambu ascope
Description: nasal route intubation by the device in fixed cancer tongue patients
Study NCT03999476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fibreroptic bronchoscope
Description: nasal route intubation by the device in fixed cancer tongue patients
Study NCT02692534 — intervention group
Intervention type: OTHER
Intervention: Urine cocaine negative
Description: Preoperative urine cocaine negative
Study NCT02692534 — intervention group
Intervention type: OTHER
Intervention: Urine cocaine positive
Description: Preoperative urine cocaine positive
Study NCT04765397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Effect of different resectoscope fluids on optic nerve diameter measured by ultrasound
Description: During the operation Blood pressure, pulse minute the number of irrigation solutions used, and intravenous serum amounts, operation time will be saved. If there is an abnormal parameters or increased optic nerve sheath surgical team will be informed.
Study NCT04305210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 PMPBB3
Description: In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.
Study NCT04305210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-florbetapir
Description: 18F-florbetapir
Study NCT03707821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A TEST Lens
Description: JJVC Investigational Contact Lens
Study NCT03707821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A CONTROL Lens
Description: Acuvue Oasys
Study NCT03409809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide and facilitator support website.
Study NCT03409809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and Technical Assistance
Description: Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide, and facilitator support website, plus half-day implementation training to further define goals, needs, leadership structure and strategy for adoption and recruitment.
Study NCT03409809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training, Tech. Assistance, Quality Assurance/Improvement
Description: Level of Support: As for Training and Technical Assistance arm, plus 1-year of technical assistance, coaching, and quality assurance to enhance skills for implementation and sustainability.
Study NCT01432444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole (Abilify®) IM Depot Injection
Description: 400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013.
Study NCT01353729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg zanamivir + moxifloxacin placebo
Description: zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
Study NCT01353729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1200 mg zanamivir + moxifloxacin placebo
Description: zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
Study NCT01353729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanamivir placebo + moxifloxacin placebo
Description: zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
Study NCT01353729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanamivir placebo + 400 mg moxifloxacin
Description: moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
Study NCT01490021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rTMS/Active TBS
Description: A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
Study NCT01490021 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS/Placebo TBS
Description: rTMS/Placebo TBS
Study NCT02439957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brincidofovir
Study NCT02439957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Study NCT01404273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation/Relaxation Response Training
Description: 1 hour weekly sessions with 20 min daily home practice for 6 weeks
Study NCT03789396 — intervention group
Intervention type: OTHER
Intervention: Targeted Normoxia (oxygen saturation 90-96%)
Description: The intervention (post-implementation) group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation
Study NCT03789396 — intervention group
Intervention type: OTHER
Intervention: Usual Care Oxygenation
Description: The control (pre-implementation) group will be trauma patients admitted to the ICU during the 12 months prior to the targeted normoxia implementation
Study NCT00546104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
Study NCT03127046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Oral single dose administration of aceclofenac 200mg
Study NCT03127046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg
Study NCT03127046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac and Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant
Study NCT01551901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal fusion
Description: Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
Study NCT02281773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 100 mg QD
Study NCT02281773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 498306 50 mg QD
Study NCT02281773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02281773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 498306 25 mg QD
Study NCT02281773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 10 mg QD
Study NCT02554695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous saline injection
Study NCT02554695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: single subcutaneous injection of denosumab 60 mg
Study NCT00293215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-Indium-CMD-193
Description: 111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.
Study NCT00293215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMD-193
Description: CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
Study NCT04284358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology integrated instruction neuromuscular training warm-up workshop
Description: Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application. This occurs for every exercise and occurs in pairs in which participants can discuss and evaluate an exercise by an exercise's key execution components.
Study NCT02318875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kritech administration
Description: 300mg/day (1 capsule) during 12 weeks; oral ingestion
Study NCT02439281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.
Study NCT02439281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
Study NCT01069757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197 and Erlotinib
Description: Orally twice daily administration of ARQ 197 and orally once daily administration of erlotinib hydrochloride
Study NCT00889005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Based Cognitive Behavioral Therapy
Description: Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
Study NCT00003249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxyamidotriazole
Study NCT00003249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT00003249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Study NCT00243035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00243035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT00243035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00800644 — intervention group
Intervention type: PROCEDURE
Intervention: CT or MRI + Blood Test
Description: During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.~Blood (about 1 tablespoon) will be drawn to test for bone turnover.
Study NCT03532347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-FNA needle (Beacon)
Description: Participants will be randomised to an initial 3 passes with Beacon FNA and then Beacon SharkCore biopsy needles or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
Study NCT01577316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Description: 2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.~It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus;~* a B/Wisconsin/1/2010-like virus.
Study NCT00331721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enecadin
Description: Dose escalating
Study NCT00331721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT04653792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: 75 mg capsule
Study NCT04653792 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 75 mg
Study NCT00779909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
Study NCT00779909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
Study NCT03638375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
Description: During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10\^8 T cells i.v.) once every three weeks for three infusions.~In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks.
Study NCT00740675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient Medication Reconciliation
Description: The post-discharge medication reconciliation module has the following features:~1. Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.~2. Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).~3. Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists).
Study NCT01737905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine HFA-MDI (E004)
Description: Single dose 125 mcg/inhalation, 2 inhalations
Study NCT01737905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-HFA
Description: Single dose 0 mcg/inhalation, 2 inhalations
Study NCT02678533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization)
Study NCT02678533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: D5 : injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)
Study NCT03896503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV
Study NCT03896503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo a tumor biopsy
Study NCT03896503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy
Study NCT03896503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03896503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03896503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT03896503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT03896503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT03896503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT01734044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin (rhTPO); dexamethasone
Description: Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
Study NCT01734044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
Study NCT04183686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470 (SAD)
Description: Single dose of ACT-1014-6470; soft capsules for oral use.
Study NCT04183686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470 (MAD)
Description: Multiple doses of ACT-1014-6470; soft capsules for oral use.